SPX3,744.52-38.76 -1.02%
DIA299.23-3.56 -1.18%
IXIC11,073.31-75.33 -0.68%

Treace Medical Shares Interim Data From Corrective Toe Surgery Trial

Benzinga · 09/14/2022 08:06
  • Treace Medical Concepts Inc (NASDAQ:TMCI) announced an audio poster presentation of the latest interim analysis from the ALIGN3D clinical study following the Lapiplasty Procedure for surgical treatment of hallux valgus (bunions).
  • The data showed:
    • Early return to weight bearing in a walking boot at an average of 8.3 days.
    • A low recurrence rate, defined as loss of radiographic correction, was observed in 1.4% of patients (2 out of 144).
    • An 81% reduction in pain (Visual Analog Scale) was reported at 24 months post-procedure (n=107).
  • The interim analysis also continued to report statistically significant improvement in Patient-Reported Outcomes. 
  • At 24 months post-surgery (n=107), an 82% and 84% improvement was observed in walking/standing and social interaction, respectively.
  • Further, statistically significant improvements in physical, mental, and social health scores were reported.
  • Price Action: TMCI shares closed 4.37% lower at $23.33 on Tuesday.